A glycan-based plasmonic sensor for prostate cancer diagnosis,Analyst

当前位置： X-MOL 学术 › Analyst › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A glycan-based plasmonic sensor for prostate cancer diagnosis
Analyst ( IF 3.6 ) Pub Date : 2021-10-01 , DOI: 10.1039/d1an00789k
Mathieu Lamarre _{1,

2} , Thomas Tremblay ₁ , Marc-Antoine Bansept _{1,

2} , Karine Robitaille ₃ , Vincent Fradet _{3,

4,

5} , Denis Giguère ₁ , Denis Boudreau _{1,

2}

Affiliation

Prostate cancer affects thousands of men who undergo clinical screening tests every year. The main biomarker used for the diagnosis of prostate cancer, prostate specific antigen (PSA), presents limitations that justify investigating new biomarkers to improve reliability. Antibodies against the tumor-associated carbohydrate antigen (Tn), or TACA, develop early in carcinogenesis, making them an interesting alternative as a target for prostate cancer diagnostics. In this work, the Tn antigen was synthesized and immobilized on a surface plasmon resonance sensor coated with a polydopamine/polyethylene oxide mixed layer used both as an anchoring surface for Tn capture moieties and to minimize surface fouling. The sensor could be regenerated and reused at least 60 times without any significant loss in sensitivity. Anti-Tn antibodies were detected in the 0–10 nM concentration range with detection limits of 0.1 and 0.3 nM in spiked buffer solutions and diluted human blood serum samples, respectively. Finally, as a proof-of-concept, this carbohydrate-based sensor was used to successfully discriminate blood serum samples from prostate cancer-free and prostate cancer patients.

中文翻译：

用于前列腺癌诊断的基于聚糖的等离子体传感器

前列腺癌影响着每年接受临床筛查测试的数千名男性。用于诊断前列腺癌的主要生物标志物前列腺特异性抗原 (PSA) 存在局限性，证明研究新的生物标志物以提高可靠性是合理的。针对肿瘤相关碳水化合物抗原 (Tn) 或 TACA 的抗体在癌变早期发展，使其成为前列腺癌诊断靶标的有趣替代品。在这项工作中，合成了 Tn 抗原并将其固定在表面等离子共振传感器上，该传感器涂有聚多巴胺/聚环氧乙烷混合层，用作 Tn 捕获部分的锚定表面并最大限度地减少表面污染。该传感器可以再生和重复使用至少 60 次，而不会显着降低灵敏度。在 0-10 nM 浓度范围内检测到抗 Tn 抗体，在加标缓冲溶液和稀释的人血清样品中的检测限分别为 0.1 和 0.3 nM。最后，作为概念验证，这种基于碳水化合物的传感器被用于成功地区分来自无前列腺癌和前列腺癌患者的血清样本。

更新日期：2021-10-08

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11